Brief: Eledon Announces Positive Topline Results From Phase 2A Trial Of Tegoprubart Demonstrating Safety, Target Engagement, And Biomarker Response In Patients Living With Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals

31/05/2022 11:24

May 31 (Reuters) - Eledon Pharmaceuticals Inc  ELDN.O :
    * ELEDON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2A
TRIAL OF
TEGOPRUBART DEMONSTRATING SAFETY, TARGET ENGAGEMENT, AND
BIOMARKER RESPONSE IN PATIENTS LIVING WITH AMYOTROPHIC LATERAL
SCLEROSIS
    * ELEDON PHARMACEUTICALS INC - TEGOPRUBART WAS
WELL-TOLERATED,
WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS
    * ELEDON PHARMACEUTICALS - BIOMARKERS REDUCED INCLUDED
BIOMARKERS
ALSO ASSOCIATED WITH IGA NEPHROPATHY AND KIDNEY ALLOGRAFT
TRANSPLANT REJECTION
    * ELEDON PHARMACEUTICALS INC - TEGOPRUBART SUCCESSFULLY MET
PRIMARY ENDPOINTS OF SAFETY AND TOLERABILITY
    * ELEDON PHARMACEUTICALS INC - ANTI-DRUG ANTIBODIES (ADAS)
WERE
PRESENT IN LESS THAN 5 PERCENT OF SAMPLES
    * ELEDON PHARMACEUTICALS INC - ALL ADAS WERE OF LOW TITER
AND DID
NOT IMPACT TEGOPRUBART DRUG LEVELS

Source text for Eikon:  ID:nGNX7W6wwC 
Further company coverage:  ELDN.O 

 ((Reuters.Briefs@thomsonreuters.com;))